Acadian Asset Management LLC purchased a new stake in Hologic, Inc. (NASDAQ:HOLX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 36,313 shares of the medical equipment provider’s stock, valued at approximately $1,648,000.
Other institutional investors have also modified their holdings of the company. TrimTabs Asset Management LLC increased its position in shares of Hologic by 88.8% in the first quarter. TrimTabs Asset Management LLC now owns 2,993 shares of the medical equipment provider’s stock valued at $127,000 after buying an additional 1,408 shares during the period. Advisor Partners LLC acquired a new position in shares of Hologic during the first quarter valued at $201,000. Miles Capital Inc. acquired a new position in shares of Hologic during the first quarter valued at $206,000. Stratos Wealth Partners LTD. acquired a new position in shares of Hologic during the first quarter valued at $210,000. Finally, Affinity Wealth Management acquired a new position in shares of Hologic during the first quarter valued at $229,000. Institutional investors own 94.46% of the company’s stock.
Shares of Hologic, Inc. (NASDAQ:HOLX) traded down 0.54% on Tuesday, hitting $38.82. The stock had a trading volume of 1,614,109 shares. The stock has a market cap of $10.89 billion, a P/E ratio of 14.46 and a beta of 0.90. Hologic, Inc. has a 12 month low of $35.15 and a 12 month high of $46.80. The firm has a 50 day moving average of $45.06 and a 200 day moving average of $42.98.
Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.01. The company had revenue of $806.10 million for the quarter, compared to analyst estimates of $799.70 million. Hologic had a return on equity of 23.18% and a net margin of 25.65%. Hologic’s revenue was up 12.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.51 earnings per share. On average, equities analysts forecast that Hologic, Inc. will post $2.01 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Acadian Asset Management LLC Purchases New Position in Hologic, Inc. (HOLX)” was posted by BBNS and is the sole property of of BBNS. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://baseballnewssource.com/markets/acadian-asset-management-llc-purchases-new-position-in-hologic-inc-holx/1408529.html.
Several brokerages recently weighed in on HOLX. Jefferies Group LLC reiterated a “buy” rating and issued a $49.00 price target on shares of Hologic in a report on Wednesday, June 28th. Barclays PLC reiterated an “overweight” rating and issued a $53.00 price target (up previously from $50.00) on shares of Hologic in a report on Monday, July 17th. BidaskClub downgraded shares of Hologic from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Stifel Nicolaus reiterated a “buy” rating on shares of Hologic in a report on Friday, July 14th. Finally, Bank of America Corporation reiterated a “neutral” rating and issued a $48.00 price target (up previously from $44.00) on shares of Hologic in a report on Friday, July 21st. Five research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $48.64.
In other Hologic news, Director Elaine Ullian sold 6,902 shares of the company’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $40.12, for a total value of $276,908.24. Following the sale, the director now owns 23,810 shares of the company’s stock, valued at $955,257.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Lawrence M. Levy sold 9,076 shares of the company’s stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $42.80, for a total value of $388,452.80. Following the completion of the sale, the director now directly owns 43,165 shares in the company, valued at approximately $1,847,462. The disclosure for this sale can be found here. Insiders sold 70,464 shares of company stock worth $3,078,921 in the last three months. 0.79% of the stock is owned by corporate insiders.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with our FREE daily email newsletter.